2023 World Conference on Lung Cancer (Posters)-EP12.01. A Multi-Center Observational Study of Effectiveness and Safety of First Line Afatinib in Major Uncommon EGFR mutated NSCLC

EP12.01. A Multi-Center Observational Study of Effectiveness and Safety of First Line Afatinib in Major Uncommon EGFR mutated NSCLC - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to investigate the effectiveness and safety of first-line afatinib treatment in Vietnamese patients with major uncommon EGFR mutation-positive non-small cell lung cancer (NSCLC). The study included 80 patients with major uncommon mutations (G719X, L861Q, S768I) out of a total of 343 patients treated with afatinib. The median age of the patients was 64 years and 30% were female. The most common starting and maintenance dose of afatinib was 30 mg once daily. <br /><br />The study found that the median time to treatment failure (TTF) was 14.7 months in all patients. Afatinib showed clinical efficacy against different major uncommon mutations, with median TTF ranging from 10.5 to 17.5 months. Patients with liver involvement had significantly inferior TTF compared to those without liver metastases. The overall response rate (ORR) and disease control rate (DCR) were 79% and 92%, respectively, in all patients. The ORR varied by mutation subtype, with higher response rates observed in patients with G719X and compound mutations. The median overall survival (OS) was not yet mature, but the 18-month survival rate was 82%. <br /><br />The most common side effects of afatinib were diarrhea, rash/acne, stomatitis, and paronychia. Only 7.6% of patients experienced grade 3 side effects. The tolerability profile of afatinib in this study was lower than reported in previous trials. Among patients tested for T790M mutation upon progression, 16% were found to have the secondary mutation. <br /><br />In conclusion, the study suggests that afatinib is an effective treatment option for Vietnamese patients with NSCLC harboring major uncommon mutations. It demonstrates encouraging survival outcomes, a high response rate, and a manageable tolerability profile. Brain and liver metastases may be poor prognostic factors, and the incidence of secondary T790M mutation was lower compared to common EGFR mutations.

Asset Subtitle

Anh Le

Meta Tag

Speaker Anh Le

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

afatinib

Vietnamese patients

EGFR mutation-positive

non-small cell lung cancer

treatment effectiveness

treatment safety

major uncommon mutations

time to treatment failure

overall response rate

side effects